MARC Record from marc_columbia

LEADER: 06020cam a22004094a 4500
001 6340114
005 20221122023717.0
008 070809t20082008paua b 001 0 eng
010 $a 2007033065
016 7 $a101313902$2DNLM
020 $a9780781773287
020 $a0781773288
029 1 $aNLM$b101313902
035 $a(OCoLC)ocn163708287
035 $a(OCoLC)163708287
035 $a(NNC)6340114
035 $a6340114
040 $aDNLM/DLC$cDLC$dNLM$dBAKER$dC#P$dOrLoB-B
042 $apcc
050 00 $aRC271.C5$bC446 2008
060 10 $aQZ 267$bC5186 2008
082 00 $a616.99/4061$222
245 04 $aThe chemotherapy source book /$ceditor, Michael C. Perry.
250 $a4th ed.
260 $aPhiladelphia :$bWolters Kluwer Health/Lippincott Williams & Wilkins,$c[2008], ©2008.
300 $axvi, 779 pages :$billustrations ;$c28 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $gSect. I.$tScientific Principles of Chemotherapy -- $g1.$tScientific Basis of Cancer Chemotherapy /$rMichael C. Perry -- $g2.$tNorton-Simon Hypothesis /$rTeresa A. Gilewski and Larry Norton -- $g3.$tDrug Resistance /$rJames H. Goldie -- $g4.$tPrinciples of Chemotherapy /$rCarl E. Freter and Michael C. Perry -- $g5.$tClinical Trials /$rBarbara K. Barrett and Jeanette A. Linebaugh -- $g6.$tHematopoietic Growth Factors /$rJeffrey Crawford and Susan Blackwell -- $g7.$tBiologic Response Modifiers: Principles of Biotherapy /$rHoward-Ozer and Carla Kurkjian -- $gSect. II.$tRoutes of Administration -- $g8.$tIntraventricular and Intrathecal Therapy /$rVictor A. Levin, Morris D. Groves and Arthur D. Forman -- $g9.$tIntraperitoneal Chemotherapy /$rMaurie Markman -- $g10.$tContinuous Intravenous Infusion Chemotherapy /$rRobert W. Carlson -- $g11.$tIntraarterial Chemotherapy /$rWilliam D. Ensminger -- $g12.$tIsolated Regional Therapy /$rJessica A. Wernberg, William G. Kraybill and John M. Kane III -- $g13.$tHematopoietic Stem Cell Transplantation /$rSteven Z. Pavletic and James O. Armitage -- $gSect. III.$tManagement of Drug Toxity -- $g14.$tOral Toxicity /$rRajesh V. Lalla, Douglas E. Peterson, Michael T. Brennan and Mark M. Schubert -- $g15.$tDermatologic Toxicity /$rSusan K. Ailor and Stacia C. Miles -- $g16.$tExtravasation /$rGerald H. Clamon -- $g17.$tHypersensitivity Reactions /$rC. Daniel Kingsley -- $g18.$tOcular Side Effects of Chemotherapy /$rMark A. Klein and Linda J. Bums -- $g19.$tCardiotoxicity of Cancer Therapy /$rJustin D. Floyd and Michael C. Perry -- $g20.$tPulmonary Toxicity of Antineoplastic Therapy /$rDaniel Morgensztern and Ramaswamy Govindan -- $g21.$tGastrointestinal Complications of Chemotherapy /$rJoel Picus and Michael Gary Martin -- $g22.$tHepatotoxicity of Chemotherapeutic Agents /$rStephen C. Medlin and Michael C. Perry -- $g23.$tRenal and Electrolyte Abnormalities Due to Chemotherapy /$rIrum Shahab and William P. Patterson -- $g24.$tChemotherapy-Induced Peripheral Neuropathy /$rFrederick Herman Hausheer -- $g25.$tVascular Toxicity of Antineoplastic Agents /$rDonald C. Doll and Nasir Shahab -- $g26.$tSecond Malignancies After Chemotherapy /$rAlfred I. Neugut and Thomas Uldrick -- $g27.$tChemotherapy in Pregnancy /$rNasir Shahab and Donald C. Doll -- $g28.$tGonadal Complications and Teratogenicity of Cancer Therapy /$rCatherine E. Klein -- $gSect. IV.$tDrug Administration -- $g29.$tCentral Venous Access for Chemotherapy /$rPaul S. Dale -- $gSect. V.$tCurrent Therapy of Specific Solid Tumors -- $g30.$tSystemic Therapy for Advanced Melanoma /$rClay M. Anderson -- $g31.$tGeneral Issues in Brain Tumor Chemotherapy /$rNancy McKinney, Susanne M. Arnold and Roy A. Patchell -- $g32.$tChemotherapy of Head and Neck Cancer /$rEverett E. Vokes and Nicholas Choong -- $g33.$tChemotherapy of Lung Cancer /$rNasser H. Hanna -- $g34.$tBreast Cancer /$rCarl G. Kardinal and John T. Cole -- $g35.$tGastrointestinal Cancer /$rChris Papageorgio -- $g36.$tEndocrine Tumors /$rStephen L. Graziano and Keith Goldstein -- $g37.$tChemotherapy of Genitourinary Cancers /$rGary R. MacVicar, Deborah A. Bradley and Maha Hussain -- $g38.$tChemotherapy of Gynecologic Cancers /$rSarah A. Holstein and Raymond J. Hohl -- $g39.$tChemotherapy of Carcinoma of Unknown Primary Site /$rJohn D. Hainsworth and F. Anthony Greco -- $g40.$tChemotherapy of Bone and Soft Tissue Sarcomas /$rRashmi Chugh, Scott M. Schuetze and Laurence H. Baker -- $g41.$tChemotherapy for Pediatric Solid Tumors /$rBarbara A. Gruner -- $gSect. VI.$tChemotherapy of Hematologic Malignancies -- $g42.$tChemotherapy of Hodgkin's Lymphoma /$rBruce A. Peterson -- $g43.$tNon-Hodgkin's Lymphoma /$rPhilip J. Bierman and James O. Armitage -- $g44.$tAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia /$rJames E. Wooldridge -- $g45.$tChemotherapy of the Myelodysplastic Syndromes /$rEkatherine Asatiani and Bruce D. Cheson -- $g46.$tManagement of Myeloproliferative Disorders and Chronic Myeloid Leukemia /$rAyalew Tefferi -- $g47.$tChemotherapy of Multiple Myeloma and Other Plasma Cell Disorders /$rNasir Shahab -- $gSect. VII.$tAppendices -- $g1.$tChemotherapeutic Agents /$rMichael C. Perry and Nancy P. McKinney -- $g2.$tChemotherapy Programs /$rMichael C. Perry and Scott McGee -- $g3.$tCommon Terminology Criteria for Adverse Events v3.0 (CTCAE) /$rMichael C. Perry.
650 0 $aCancer$xChemotherapy.$0http://id.loc.gov/authorities/subjects/sh85019497
650 0 $aAntineoplastic agents.$0http://id.loc.gov/authorities/subjects/sh85005714
650 12 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
650 22 $aAntineoplastic Agents$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000970Q000627
700 1 $aPerry, Michael C.$q(Michael Clinton),$d1945-$0http://id.loc.gov/authorities/names/n84026152
856 42 $3Publisher description$uhttp://www.loc.gov/catdir/enhancements/fy0743/2007033065-d.html
852 00 $boff,hsl$hRC271.C5$iC446 2008